This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hermansky-Pudlak syndrome, HPS헤르만스키-푸들라크증후군

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E70.3 (albinism) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsHPS, Albinism-platelet storage pool deficiency, HPS types 1~11, Hermansky-Pudlak syndrome
C. Adult onsetLikelihood of first onset in adulthood low (but pulmonary fibrosis presents in adulthood) — oculocutaneous albinism and bleeding tendency are present from birth, but pulmonary fibrosis (HPS-1/HPS-4 types) progresses after the 30s, and many cases are first diagnosed when the patient presents as an adult.
1. HistoryFirst described in 1959 by the Czech physicians Hermansky and Pudlak → recognized in 1974 as an albinism-bleeding diathesis syndrome → HPS gene group identified in the 2000s → 11 subtypes elucidated.
2. CausesHPS1~HPS11 gene mutations → defects in lysosome-related organelle (LRO) biogenesis complexes (BLOC-1, -2, -3, AP-3) → abnormalities of melanosomes, platelet dense granules, and lamellar bodies.
3. GeneticsAutosomal recessive. HPS1 (10q23), HPS2/AP3B1 (5q14), HPS3 (3q24), HPS4 (22q12), HPS5 (11p15), HPS6 (10q24), HPS7-11. High frequency of HPS1 in northwestern Puerto Rico (1/1800).
4. General epidemiologyWorldwide prevalence about 1/500,000~1/1,000,000. Northwestern Puerto Rico 1/1800 (HPS1). Korea: extremely rare (fewer than a few dozen reported).
5. PathophysiologyBLOC/AP-3 complex defects → melanin deficiency in melanosomes (oculocutaneous albinism) + absent platelet dense granules (bleeding diathesis) + defective lamellar bodies in type II alveolar cells (pulmonary fibrosis).
6. SymptomsOculocutaneous albinism (reduced vision, nystagmus, strabismus), bleeding tendency (petechiae, abnormal bruising, excessive postoperative bleeding), pulmonary fibrosis (exertional dyspnea, cough), granulomatous colitis, immunodeficiency (HPS-2).
7. SignsReduced skin and hair pigmentation, iris transillumination, nystagmus, foveal hypoplasia, prolonged bleeding time (normal platelet aggregation, absent dense granules), ground-glass opacity and interlobular septal thickening on HRCT.
8. ScreeningNot a target of general newborn screening. Electron microscopy (absent platelet dense granules) and an HPS gene panel are recommended when there is a history of oculocutaneous albinism + bleeding diathesis.
9. DiagnosisPlatelet electron microscopy (confirming loss of dense granules), gene panel (HPS1~11), pulmonary function tests and HRCT (assessment of pulmonary fibrosis), platelet aggregation testing (ADP and collagen abnormalities).
10. TreatmentNo curative treatment. Pirfenidone (slowing progression of pulmonary fibrosis), hemostatic support (DDAVP, transfusion), visual aids and light shielding, management of immunodeficiency (HPS-2: IVIG/hematopoietic stem cell transplantation), lung transplantation (end stage).
11. PrognosisPulmonary fibrosis is the main cause of death (50% die before age 50, HPS-1/4 types). In the HPS-3 type, pulmonary fibrosis is rare and the prognosis is favorable. Early intervention is possible with proactive surveillance.
12. PreventionGenetic counseling and prenatal testing (in affected families), UV protection (skin cancer prevention), avoidance of drugs that increase bleeding risk (aspirin, NSAIDs), regular pulmonary function monitoring.
13. ReferencesGahl WA et al. Hermansky-Pudlak Syndrome. N Engl J Med. 2002;347:959-969 … and 9 other papers

1. History

Hermansky-Pudlak syndrome (HPS) was first named in a 1959 paper in which the Czechoslovak internists František Hermanský and Pavlus Pudlák described two patients who simultaneously showed oculocutaneous albinism, a bleeding tendency, and accumulation of ceroid in tissues. The two authors reported this unusual triple combination of clinical features in the Czech medical journal Čas Lék čes, and it was subsequently also published in English in the same year, attracting the attention of the international academic community.

Initially it was simply classified as a 'bleeding diathesis syndrome with albinism,' but from the 1970s, advances in electron microscopy began to reveal the core cellular pathological feature of this syndrome, absence of platelet dense granules. Absence of platelet dense granules was shown to be a form of platelet storage pool deficiency, causing impaired release of ADP, ATP, serotonin, and calcium. In 1972, White, Hiram, and colleagues confirmed the complete loss of platelet dense granules by electron microscopy.

In the 1980s~90s, the research team of Gahl at the US National Institutes of Health (NIH) identified a high-prevalence HPS population in northwestern Puerto Rico and systematically studied the epidemiology, clinical features, and pathophysiology of HPS in this population, laying the cornerstone of current HPS research. In northwestern Puerto Rico, the prevalence of HPS type 1 was confirmed to reach about 1/1800, which was shown to be due to a founder effect in that region.

With the advent of the molecular genetics era, the genetic heterogeneity of HPS became apparent. The HPS1 gene was first identified in 1996, and subsequently AP3B1 (HPS-2), HPS3, HPS4, HPS5, HPS6, and others were identified in turn, so that by the end of the 2010s a total of 11 HPS genes (HPS1~HPS11) had been confirmed. The proteins encoded by each gene were shown to be components of complexes (BLOC-1, BLOC-2, BLOC-3, AP-3, etc.) essential for the biogenesis of lysosome-related organelles (LROs).

Clinically, pulmonary fibrosis was identified as the most important life-threatening complication in patients with HPS-1 and HPS-4 types, and in 2002 Naidu and colleagues and Gahl and colleagues reported the inhibitory effect of pirfenidone on pulmonary fibrosis in the first randomized controlled trial. This result is regarded as an important milestone that first suggested the possibility of applying antifibrotic agents to HPS. Recently, in 2025, research exploring the possibility of molecularly targeted therapy for lysosome-related organelle biogenesis complexes is actively under way.

Reports of HPS in Korea are very rare, and according to data from the Korean Society of Medical Genetics and the Korea Rare and Intractable Disease Information Center, fewer than a few dozen confirmed patients have been reported. In Korea, HPS is often discovered following a diagnosis of albinism, mainly through pediatrics and ophthalmology, and the importance of a multidisciplinary approach for surveillance of the complication of pulmonary fibrosis is emphasized.


2. Causes

Hermansky-Pudlak syndrome is an autosomal recessive genetic disorder caused by pathogenic mutations in genes encoding complex proteins responsible for the biogenesis and function of lysosome-related organelles (LROs). To date, 11 causative genes have been identified, and they are broadly classified into groups encoding components of the BLOC-1 (Biogenesis of Lysosome-related Organelle Complex-1), BLOC-2, BLOC-3, and AP-3 (Adaptor Protein-3) complexes.

The BLOC-3 complex consists of the HPS1 and HPS4 proteins and is essential for intracellular transport of lysosomal membrane proteins and melanosome maturation. Mutations in the HPS1 gene (10q23.1) cause HPS-1, the most common HPS subtype, and a founder mutation (16-bp duplication) is found at high frequency particularly in residents of northwestern Puerto Rico. Mutations in the HPS4 gene (22q12.1) cause HPS-4. BLOC-3 defects are associated with highly penetrant pulmonary fibrosis.

The AP-3 complex consists of subunits such as AP3B1 (HPS-2, 5q14.1) and AP3D1 (HPS-10) and mediates protein transport to lysosome-related organelles. AP3B1 mutations cause HPS-2, a subtype with a distinctive phenotype in which pulmonary fibrosis appears early, in childhood or young adulthood, accompanied by immunodeficiency (neutropenia, reduced NK cell function). The BLOC-2 complex includes the HPS3 (3q24), HPS5 (11p15.1), and HPS6 (10q24.32) proteins, and in HPS subtypes due to BLOC-2 defects, pulmonary fibrosis is rare or mild, and the prognosis is relatively favorable. The BLOC-1 complex consists of multiple subunits, including DTNBP1 (HPS-7), BLOC1S3 (HPS-8), BLOC1S6 (HPS-9), and BLOC1S5 (HPS-11).

At the cellular level, functional defects of these complexes commonly impair the biogenesis of lysosome-related organelles and cargo transport. Specifically, (1) poor melanin synthesis and accumulation in the melanosomes of melanocytes, (2) inability to store ADP, ATP, serotonin, and calcium in platelet dense granules (δ-granules), and (3) abnormal storage and secretion of surfactant in the lamellar bodies of type II alveolar epithelial cells occur respectively, producing the three major clinical features of oculocutaneous albinism, bleeding diathesis, and pulmonary fibrosis. Rarely, lysosomal dysfunction in colonic mucosal cells causes granulomatous colitis.


3. Genetics

Hermansky-Pudlak syndrome follows an autosomal recessive mode of inheritance, and males and females are affected with equal frequency. The 11 causative genes currently identified (HPS1, AP3B1/HPS2, HPS3, HPS4, HPS5, HPS6, DTNBP1/HPS7, BLOC1S3/HPS8, BLOC1S6/HPS9, AP3D1/HPS10, BLOC1S5/HPS11) are located on different chromosomes, and each encodes a component of an independent LRO biogenesis complex.

Genotype-phenotype correlations are closely tied to the type of complex. BLOC-3 defects (HPS-1, HPS-4): highly penetrant pulmonary fibrosis; AP-3 defects (HPS-2): childhood pulmonary fibrosis + immunodeficiency; BLOC-2 defects (HPS-3, -5, -6): pulmonary fibrosis absent or rare, bleeding and albinism the main symptoms; BLOC-1 defects (HPS-7~11): mild bleeding, pigmentary abnormalities, some neurological abnormalities reported.

HPS1 mutations show various founder effects by region. In northwestern Puerto Rico the 16-bp duplication mutation (c.1470_1485dup16) predominates, and in Japan the IVS5+1G>T splice site mutation predominates. In Korean and other Asian patients, various private mutations are reported, and in Korea the HPS1 and HPS3 subtypes are mainly reported. Because the clinical course differs greatly between subtypes, subtype classification through genetic confirmation is essential for predicting the prognosis of individual patients and planning surveillance for pulmonary fibrosis. Next-generation sequencing (NGS) panel testing is currently used as the clinical standard diagnostic method, and variant pathogenicity is classified by comparison with variant databases (ClinVar, HGMD).

Heterozygous carriers are generally asymptomatic, but there are reports that their platelet dense granule count may be about 50% of normal, so caution may be required before surgery. Prevention is possible through preimplantation genetic testing (PGT-M) and prenatal molecular genetic testing, which are actively recommended in families that already have a child with HPS.


4. General epidemiology

The worldwide prevalence of Hermansky-Pudlak syndrome is estimated at about 1/500,000~1/1,000,000, making it a very rare disease. However, markedly high prevalence is observed in certain regional populations because of a founder effect. The best-known example is northwestern Puerto Rico, where the prevalence of HPS type 1 reaches about 1/1,800 and the carrier frequency is estimated at about 1/21. Relatively high frequencies have also been reported in parts of central Switzerland and certain regions of Japan.

Because of autosomal recessive inheritance, the sex distribution is equal between males and females. By age, oculocutaneous albinism and bleeding diathesis are present from birth, but pulmonary fibrosis becomes clinically prominent mainly in HPS-1/4 types as symptoms intensify in the 30s~50s. In the HPS-2 type, immunodeficiency is present because of the role of the AP-3 complex, and serious infectious complications sometimes occur in childhood. Worldwide, HPS-1 is reported to be the most common subtype and HPS-3 the second most common.

Epidemiological data in Korea are limited. According to Korean rare disease registration data, fewer than a few dozen confirmed patients have been reported, and there are presumed to be more patients who have not actually been diagnosed. This is because HPS may not be recognized as a cause of oculocutaneous albinism and may be classified as simple albinism, or, when the bleeding diathesis is mild, it may be mistaken for another cause. There are also cases first diagnosed as HPS in adulthood when the complication of pulmonary fibrosis appears. Worldwide, the prevalence of HPS is similar in males and females, and outside specific ethnic groups or regions it is known to be distributed without bias.


5. Pathophysiology

The core pathophysiology of Hermansky-Pudlak syndrome is impaired biogenesis and cargo transport of lysosome-related organelles (LROs). LROs are specialized organelles that share characteristics with lysosomes but perform cell type-specific functions, and include melanosomes of melanocytes, dense granules (δ-granules) of platelets, lamellar bodies of type II alveolar epithelial cells, lytic granules of cytotoxic T lymphocytes and NK cells, and α-granules of platelets.

The BLOC-1, BLOC-2, BLOC-3, and AP-3 complexes encoded by the HPS genes regulate the intracellular vesicle transport pathway that delivers membrane protein cargo produced in the endoplasmic reticulum to LROs via endosomes. When these complexes are defective, targeted transport to LROs of LRO-specific membrane proteins (melanosomal proteins such as TYRP1 and OCA2; dense granule proteins such as CD63 and LAMP-2; lamellar body proteins such as ABCA3) is disrupted. As a result, these proteins are missorted to lysosomes and degraded, or LRO maturation is inhibited, resulting in loss of function.

Oculocutaneous albinism results from reduced melanin production due to poor transport of melanin-synthesizing enzyme proteins such as TYRP1 and OCA2 to melanosomes. The bleeding tendency occurs because the inability of platelet dense granules to store ADP, ATP, and serotonin weakens the platelet activation signal (second wave), making the hemostatic response insufficient. Primary platelet thrombus formation (adhesion and aggregation) depends on the vWF and GPIIb/IIIa pathways and is relatively preserved, but the absence of ADP and serotonin secretion means that the signal reinforcing platelet aggregation is lacking. Pulmonary fibrosis is understood to result from impaired normal storage and secretion of surfactant (mainly dependent on ABCA3 transport) in the lamellar bodies of type II alveolar epithelial cells and the sustained release of profibrotic factors such as TGF-β from damaged epithelial cells, leading to progressive interstitial pulmonary fibrosis. BLOC-3 defects (HPS-1/4) are particularly vulnerable in this pathway because BLOC-3 is specifically involved in lamellar body maturation.


6. Symptoms

The clinical symptoms of Hermansky-Pudlak syndrome consist broadly of three major symptoms (oculocutaneous albinism, bleeding tendency, pulmonary fibrosis) and additional symptoms that appear in some subtypes (granulomatous colitis, immunodeficiency).

Oculocutaneous albinism (OCA) is the most obvious phenotype, present from birth. Reduced pigmentation of the skin, hair, and eyebrows appears variably, showing a spectrum of hypopigmentation rather than complete whiteness, in contrast to other OCA subtypes. Ocular symptoms include nystagmus, reduced visual acuity (usually around 0.1~0.4), strabismus, refractive errors, photosensitivity, and foveal hypoplasia, and impaired binocular vision due to misrouted optic chiasm fibers is also common.

The bleeding tendency reflects a mild to moderate hemostatic disorder due to absent platelet dense granules. The main symptoms are petechiae, ecchymoses (unusual bruising), gum bleeding, epistaxis, menorrhagia, and excessive bleeding after surgery or tooth extraction. Intracranial hemorrhage and spontaneous joint bleeding are rare, which distinguishes it from hemophilia, but hemostatic measures must be planned before major surgery.

Pulmonary fibrosis is a progressive interstitial lung disease that appears after the 30s~40s in HPS-1 and HPS-4 types, beginning with exertional dyspnea, dry cough, and a gradual decline in exercise capacity. It can usually lead to respiratory failure and death within 10 years of symptom onset, making it the most important prognostic factor in HPS. Granulomatous colitis may present with a Crohn's disease-like clinical picture in HPS-1, HPS-3, and HPS-4 types, with abdominal pain, diarrhea, bloody stools, and mucoid stools as the main symptoms. Immunodeficiency is specific to HPS-2 (AP3B1 mutations), and complications such as recurrent infections, neutropenia, reduced NK cell function, and HLH (hemophagocytic lymphohistiocytosis) may occur. In addition, renal dysfunction, cardiomyopathy, and others are rarely reported in some patients.


7. Signs

The characteristic signs of HPS are identified on physical examination and testing. Skin, hair, and eyes: generalized reduced skin pigmentation (spectrum from complete whiteness to mild hypopigmentation), reduced hair pigmentation (pale yellow~white), reduced iris pigmentation and translucency (red reflex on retroillumination), nystagmus, strabismus, refractive errors. Fundus examination shows absent foveal reflex and hypopigmentation of the retinal pigment epithelium.

Bleeding-related test findings: complete blood count (CBC) shows a normal or slightly reduced platelet count. Prolonged bleeding time (BT) or prolonged PFA-100 closure time. PT and aPTT are normal. Platelet aggregation testing shows a reduced or absent second wave of aggregation in response to ADP and collagen. On flow cytometry, platelet surface P-selectin expression is normal but CD63 (a dense granule marker) expression is reduced. Electron microscopy is the most useful test for confirmation, showing complete loss or marked reduction of platelet dense granules. Normal platelets show 1~9 dense granules per platelet, but in HPS patients this is greatly reduced to 0~1.

Pulmonary: chest HRCT shows bilateral ground-glass opacity, interlobular septal thickening, reticular opacities, and honeycomb changes in the late stage. Pulmonary function testing (PFT) shows a restrictive pattern (reduced FVC, reduced TLC) and reduced DLCO. Specific ceroid pigment deposition derived from lamellar bodies (PAS-positive) may be identified in bronchoalveolar lavage fluid (BAL) or lung tissue biopsy.

Gastrointestinal: colonoscopy and biopsy may show Crohn's disease-like granulomatous inflammation and mucosal ulcers. HPS-related colitis is histologically similar to ordinary Crohn's disease and may be difficult to differentiate, and HPS genetic testing is essential for confirmation. HPS-2 immunodeficiency: peripheral blood neutropenia (absolute neutrophil count below 1,500/μL), reduced NK cell activity, hypogammaglobulinemia, etc.


8. Screening

Hermansky-Pudlak syndrome is not currently included in general newborn screening panels. However, HPS must be considered in the differential diagnosis of all patients with clinically confirmed oculocutaneous albinism, particularly when albinism is accompanied by a bleeding diathesis (unusual bruising, epistaxis, excessive postoperative bleeding).

Criteria for suspecting HPS: when (1) oculocutaneous albinism (nystagmus, reduced vision, hypopigmentation) is accompanied by + (2) a bleeding tendency (mild~moderate bleeding consistent with dense granule deficiency) or (3) unexplained interstitial lung disease (particularly in the 30s~50s). HPS genetic testing is recommended even in cases with OCA alone without a bleeding diathesis, because dense granule deficiency may not have been clinically recognized.

Order of initial testing: in step 1, complete blood count, bleeding time or PFA-100, and platelet aggregation testing are performed to screen for platelet dysfunction; in step 2, platelet dense granule count is checked by electron microscopy; and in step 3, confirmation and subtype classification are performed by NGS-based HPS gene panel testing. If the subtype is identified as HPS-1/4, regular pulmonary function testing and HRCT for surveillance of pulmonary fibrosis are recommended. Carrier testing of family members should also be offered as part of the genetic counseling process.

Registration for Korean rare and intractable disease Special Copayment Reduction (V117) requires meeting the diagnostic criteria, including clinical criteria and genetic test results, and when the attending physician applies for Special Copayment Reduction, the relevant test reports and a medical certificate must be submitted together.


9. Diagnosis

Hermansky-Pudlak syndrome is confirmed in three steps: clinical findings + electron microscopy + genetic testing.

Clinical diagnostic criteria: HPS is strongly suspected when oculocutaneous albinism (reduced vision, nystagmus, hypopigmentation) is accompanied by one or more of platelet dense granule deficiency or pulmonary fibrosis. OCA alone requires differentiation from other causes such as OCA1~4, Chediak-Higashi, and Cross syndrome.

Electron microscopy (EM): the number of platelet dense granules is counted directly by electron microscopy (usually transmission electron microscopy, TEM, or whole-mount EM). Normal platelets show 1~9 dense granules per platelet, but in HPS patients this is extremely reduced to 0~0.5 per platelet. This test requires technical expertise and can be performed only at specialized institutions.

Platelet function tests: loss of the second wave of aggregation in response to ADP and collagen on the PFA-100 (collagen/ADP cartridge) or the platelet aggregation test is functional evidence of dense granule deficiency. However, this abnormality can also occur in other disorders with dense granule deficiency (gray platelet syndrome, etc.), so it is not specific.

Gene panel testing: currently the most recommended confirmatory method is NGS panel testing that includes the HPS1~HPS11 genes. When a mutation is found, subtype classification is possible, allowing early identification of the group at risk of pulmonary fibrosis (BLOC-3 defect group) and the group at risk of immunodeficiency (AP-3 defect group). In Korea, this panel test is offered by clinical genomics laboratories at some university hospitals and by external reference laboratories.

Assessment of pulmonary fibrosis: in patients confirmed to have HPS-1/4 types, pulmonary function testing (FVC, DLCO) 1~2 times a year from the asymptomatic stage and chest HRCT every 2~3 years are recommended. Reduced DLCO has been reported as the earliest indicator of pulmonary fibrosis. When there are colonic symptoms, HPS-related colitis is evaluated by colonoscopy and biopsy.


10. Treatment

There is currently no curative treatment for Hermansky-Pudlak syndrome, and symptomatic treatment of each clinical feature and prevention of complications are the core of treatment.

Treatment of pulmonary fibrosis: pirfenidone is currently the best-evidenced drug treatment for HPS-related pulmonary fibrosis. A 2002 randomized controlled trial (Gahl et al., N Engl J Med) showed that the rate of FVC decline was significantly slowed in the pirfenidone group (a difference of about 400 mL/year). Similar results were confirmed in subsequent studies, with the clearest effect reported in patients with HPS type 1. Application to HPS of nintedanib, approved for IPF (idiopathic pulmonary fibrosis), is also being tried in some cases, but evidence is limited. Lung transplantation may be considered in patients with end-stage pulmonary fibrosis, but because of the high surgical risk due to the bleeding diathesis of HPS, the decision should be made carefully at a specialized center.

Treatment of bleeding: administration of DDAVP (desmopressin) 0.3 μg/kg intravenously or by nasal spray before surgery or procedures has the effect of releasing vWF and FVIII and temporarily improving platelet function. However, because the dense granules themselves are absent, a response to DDAVP occurs only in some patients, so it is advisable to confirm the response in advance with a trial dose. Platelets for transfusion are used for major surgery or massive bleeding rather than spontaneous bleeding, and irradiated, leukocyte-reduced apheresis platelets are preferred to prevent HLA antibody formation. Antifibrinolytic agents such as aminocaproic acid (epsilon-aminocaproic acid, EACA) and tranexamic acid are also used as hemostatic adjuncts. Platelet-inhibiting drugs such as aspirin, NSAIDs, and clopidogrel are contraindicated.

Ophthalmic management: vision correction with corrective lenses (glasses, contact lenses), and management of photosensitivity with UVA/UVB-blocking sunglasses, wide-brimmed hats, etc. Treatment of strabismus (surgery or prism correction) is also performed when needed. Granulomatous colitis: general Crohn's disease treatment protocols such as 5-ASA agents, corticosteroids, and azathioprine are followed. HPS-2 immunodeficiency: intravenous immunoglobulin (IVIG) for recurrent infections; hematopoietic stem cell transplantation is considered for severe immunodeficiency and HLH. Gene therapy and cell therapy research is exploring the possibility of restoring melanosomes and lamellar bodies but has not reached the clinical stage.


11. Prognosis

The prognosis of Hermansky-Pudlak syndrome differs markedly by subtype. In HPS-1 and HPS-4 types, pulmonary fibrosis is highly penetrant, and many patients die of respiratory failure within about 10 years of the diagnosis of pulmonary fibrosis. Overall, 50% of patients with HPS type 1 are reported to die of pulmonary fibrosis before age 50. Unlike HPS type 1, HPS type 3 rarely develops pulmonary fibrosis and has a relatively favorable prognosis, with the bleeding tendency and visual impairment due to albinism as the main sources of morbidity. In HPS type 2, immunodeficiency due to AP-3 deficiency is the main risk factor, and recurrent infections and HLH complications in childhood can be life-threatening.

The bleeding tendency is usually mild~moderate and spontaneous life-threatening bleeding is rare, but serious complications can occur if surgery is approached carelessly. Because the risk of skin cancer (particularly squamous cell carcinoma, basal cell carcinoma, and melanoma) is increased by UV exposure, active photoprotection is important. Current clinical practice pursues a strategy of slowing the progression of pulmonary fibrosis and maintaining quality of life through pirfenidone use, regular pulmonary function monitoring, and multidisciplinary management, and improved prognosis is expected in the future as gene therapy research advances.


12. Prevention

Because Hermansky-Pudlak syndrome is a genetic disorder, fundamental prevention is achieved through genetic counseling and reproductive options. For couples identified as HPS patients or carriers, prenatal genetic testing (fetal DNA testing through chorionic villus sampling or amniocentesis) and preimplantation genetic testing (PGT-M) can be offered, enabling prenatal diagnosis or selection of unaffected embryos. In high-prevalence regions such as northwestern Puerto Rico in particular, population genetic screening is being performed.

In patients who are already affected, secondary prevention of complications is key. Skin cancer prevention: routine UV protection (applying sunscreen of SPF 50 or higher, UVA/UVB-blocking sunglasses, wearing a hat, limiting outdoor activity during the daytime). Bleeding prevention: avoidance of platelet-inhibiting drugs such as aspirin, NSAIDs, and clopidogrel; hematology consultation and planning of hemostatic measures (DDAVP, tranexamic acid, etc.) before all invasive procedures; informing medical institutions of the HPS diagnosis and dense granule deficiency when visiting. Pulmonary fibrosis monitoring: pulmonary function testing (FVC, DLCO) 1~2 times a year and HRCT every 2~3 years in HPS-1/4 patients; if pulmonary fibrosis is detected early, early pirfenidone to slow progression. Ophthalmic care: regular ophthalmic follow-up (surveillance for refractive errors, strabismus, cataract), minimizing UV exposure. Infection prevention (HPS type 2): standard vaccinations, prophylactic antimicrobials or IVIG if needed. Establishing an integrated follow-up system by a multidisciplinary team (ophthalmology, hematology, pulmonology, medical genetics, gastroenterology) is recommended.


13. References

  1. Gahl WA, Brantly M, Kaiser-Kupfer MI, et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med. 1998;338(18):1258-1264. doi:10.1056/NEJM199804303381803
  2. Gahl WA, Huizing M. Hermansky-Pudlak Syndrome. In: Adam MP, et al., eds. GeneReviews [Internet]. Seattle: University of Washington; 2000 Jul 24 [updated 2023]. PMID: 20301464
  3. Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet. 2008;9:359-386. doi:10.1146/annurev.genom.9.081307.164303
  4. Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab. 2002;76(3):234-242. doi:10.1016/S1096-7192(02)00044-6
  5. Carmona-Rivera C, Golas G, Hess RA, et al. Clinical, molecular, and cellular features of non-Puerto Rican Hermansky-Pudlak syndrome patients of Hispanic descent. J Invest Dermatol. 2011;131(12):2394-2400. PMID: 21900949
  6. Vicary GW, Vergne Y, Santiago-Cornier A, Young LR, Roman J. Pulmonary fibrosis in Hermansky-Pudlak syndrome. Ann Am Thorac Soc. 2016;13(10):1839-1846. doi:10.1513/AnnalsATS.201603-174FR
  7. Westbroek W, Adams D, Huizing M, et al. Cellular defects in Chediak-Higashi syndrome correlate with the molecular genotype and clinical phenotype. J Invest Dermatol. 2007;127(11):2674-2677. PMID: 17554375
  8. Grucela AL, Patel P, Goldstein E, Magro C, Shapiro R, Legnani PE. Granulomatous enterocolitis associated with Hermansky-Pudlak syndrome. Am J Gastroenterol. 2006;101(9):2090-2095. PMID: 16930153
  9. Witkop CJ, Nunez Babcock M, Rao GH, et al. Albinism and Hermansky-Pudlak syndrome in Puerto Rico. Bol Asoc Med P R. 1990;82(8):333-339. PMID: 2241131
  10. Tondi A, et al. Hermansky-Pudlak Syndrome: From Molecular Pathogenesis to Targeted Therapies. IUBMB Life. 2025;77:e70025. doi:10.1002/iub.70025